An Overview and Management of Painful Menstrual Disorder (Dysmenorrhea): A Narrative Literature Review

In: Sriwijaya Journal of Obstetrics and Gynecology · 2023 · vol. 1(1) , pp. 27–29 · doi:10.59345/sjog.v1i1.23 · W4377964359
article OA: diamond CC0 ⤵ 1 in-corpus citation
AI-generated summary by gemini-2.5-flash-lite, 2026-06-10

This literature review describes primary dysmenorrhea as prostaglandin-mediated menstrual pain in ovulatory cycles, and secondary dysmenorrhea as pain linked to pelvic pathology, with NSAIDs recommended as the primary treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text

This narrative literature review describes painful menstrual disorder (dysmenorrhea), distinguishing primary dysmenorrhea, attributed to prostaglandin release in ovulatory cycles without pelvic disease, from secondary dysmenorrhea, linked to pelvic pathology that can arise in later reproductive years. It reports that dysmenorrhea affects about 90% of women, with roughly 15% experiencing pain severe enough to prevent activities for 1–3 days, and notes that primary dysmenorrhea often begins in adolescence. The review states that nonsteroidal anti-inflammatory drugs (NSAIDs) are the treatment of choice because they reduce cyclooxygenase (COX) activity and thereby prostaglandin production, and highlights that NSAIDs are most effective when initiated at the first sign of bleeding or cramping. This paper is centrally about dysmenorrhea; relevance to endometriosis: it explicitly lists secondary dysmenorrhea as associated with pelvic diseases including endometriosis and adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Primary dysmenorrhea is menstrual pain associated with the release of prostaglandins in the ovulatory cycle, but not with the pelvic disease. Approximately 90% of all women experience dysmenorrhea, 15% of whom are unable to last 1 to 3 days because of the severity of the pain. This literature review aimed to describe an overview and management of dysmenorrhea. Primary dysmenorrhea usually begins with the onset of ovulation cycles, with the highest prevalence in adolescence. In contrast, secondary dysmenorrhea is associated with pelvic pathology (i.e., ovarian cysts, adenomyosis, endometriosis) that manifests in later reproductive years and can occur at any point in the menstrual cycle. Administration of nonsteroidal anti-inflammatory drugs (NSAIDs) is the treatment of choice because these drugs reduce the activity of the cyclooxygenase (COX) enzyme and, thus, the production of prostaglandins. NSAIDs work in the majority of women with primary dysmenorrhea and are most effective when started at the first sign of bleeding or cramping.
Full text 1,363 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Primary dysmenorrhea is menstrual pain associated with the release of prostaglandins in the ovulatory cycle, but not with the pelvic disease. Approximately 90% of all women experience dysmenorrhea, 15% of whom are unable to last 1 to 3 days because of the severity of the pain. This literature review aimed to describe an overview and management of dysmenorrhea. Primary dysmenorrhea usually begins with the onset of ovulation cycles, with the highest prevalence in adolescence. In contrast, secondary dysmenorrhea is associated with pelvic pathology (i.e., ovarian cysts, adenomyosis, endometriosis) that manifests in later reproductive years and can occur at any point in the menstrual cycle. Administration of nonsteroidal anti-inflammatory drugs (NSAIDs) is the treatment of choice because these drugs reduce the activity of the cyclooxygenase (COX) enzyme and, thus, the production of prostaglandins. NSAIDs work in the majority of women with primary dysmenorrhea and are most effective when started at the first sign of bleeding or cramping.

Keywords

Article Details Sriwijaya Journal of Obstetrics and Gynecology (SJOG) allow the author(s) to hold the copyright without restrictions and allow the author(s) to retain publishing rights without restrictions, also the owner of the commercial rights to the article is the author.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosisdysmenorrhea

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

References (6)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK